Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abiraterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 16/20 | 1.00 |
| ▸ | AR known ✓ | P10275 | 1/20 | 0.71 |
| ▸ | CYP21A2 | P08686 | 6/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 3/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abiraterone SCHEMBL15700283 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL16439307 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL16383633 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL16381720 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL23924960 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL17384662 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL25074918 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL17384634 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL22414103 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL19724576 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3890749-B1 | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250197432-A1 | CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer | SUMITOMO PHARMA ONCOLOGY INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-03-27 | — | — | US | disclosed |
| US-20240391883-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-11-28 | — | — | US | disclosed |
| EP-4446301-A2 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2024-10-16 | — | — | EP | disclosed |
| US-12077554-B2 | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-3988541-B1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2024-06-26 | — | — | EP | disclosed |
| US-11919874-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-03-05 | — | — | US | disclosed |
| EP-3442942-B1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2023-11-15 | — | — | EP | disclosed |
| US-11779550-B2 | Bisphenol ether derivatives and methods for using the same | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-10-10 | — | — | US | disclosed |
| EP-2744773-B1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY (CA) | 2016-11-02 | — | — | EP | disclosed |
| US-9365510-B2 | Aziridine bisphenol ethers and related compounds and methods for their use | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2016-06-14 | — | — | US | disclosed |
| US-20150010469-A1 | BISPHENOL ETHER COMPOUNDS WITH NOVEL BRIDGING GROUPS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-01-08 | — | — | US | disclosed |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-04 | — | — | US | disclosed |
| EP-2744773-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2014-06-25 | — | — | EP | disclosed |
| US-20130336962-A1 | AZIRIDINE BISPHENOL ETHERS AND RELATED COMPOUNDS AND METHODS FOR THEIR USE | The University of Biritish Columbia (CA) | 2013-12-19 | — | — | US | disclosed |
| WO-2013028572-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2013-02-28 | — | — | WO | disclosed |
| US-20130045204-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-02-21 | — | — | US | disclosed |
| WO-2012145330-A1 | FLUORENE-9-BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012145328-A1 | DIBENZYLPHENYL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | AR, SHBG, NR5A1 | CYP17A1 13/4885AR 1/4885CYP21A2 46/4885 |
| US-20240391883-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | AR, KLK3, GNRHR | CYP17A1 23/4885AR 1/4885CYP21A2 86/4885 |
| US-20130336962-A1 | AZIRIDINE BISPHENOL ETHERS AND RELATED COMPOUNDS AND METHODS FOR THEIR USE | ESR1, AR, ESR2 | CYP17A1 784/4885AR 2/4885CYP21A2 476/4885 |
| US-20130045204-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | AR, ESRRA, ESR1 | CYP17A1 208/4885AR 1/4885CYP21A2 180/4885 |
| US-20150010469-A1 | BISPHENOL ETHER COMPOUNDS WITH NOVEL BRIDGING GROUPS AND METHODS FOR THEIR USE | AR, ESR2, ESR1 | CYP17A1 99/4885AR 1/4885CYP21A2 91/4885 |
| US-11919874-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | AR, SHBG, NR5A1 | CYP17A1 13/4885AR 1/4885CYP21A2 46/4885 |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | AR, SHBG, ESRRA | CYP17A1 90/4885AR 1/4885CYP21A2 113/4885 |
| US-11779550-B2 | Bisphenol ether derivatives and methods for using the same | AR, SHBG, ESRRA | CYP17A1 21/4885AR 1/4885CYP21A2 25/4885 |
| US-20250197432-A1 | CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer | CDK9, CDK19, CDK7 | CYP17A1 3103/4885AR 2470/4885CYP21A2 2838/4885 |
| US-12077554-B2 | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | CDK9, CDK19, CDK7 | CYP17A1 3103/4885AR 2470/4885CYP21A2 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.